{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:00:00Z","timestamp":1790146800299,"version":"4.0.1"},"update-to":[{"DOI":"10.1002\/14651858.cd015907","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000}}],"reference-count":178,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015907.pub2","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T16:08:43Z","timestamp":1763050123000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Thiazolidinediones for people with chronic kidney disease and diabetes"],"prefix":"10.1002","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2825-2993","authenticated-orcid":false,"given":"Patrizia","family":"Natale","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"},{"name":"Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J); University of Bari Aldo Moro; Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suetonia C","family":"Green","sequence":"additional","affiliation":[{"name":"Department of Medicine; University of Otago Christchurch; Christchurch New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Tunnicliffe","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pellegrino","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J); University of Bari Aldo Moro; Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Toyama","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Faculty of Medical Sciences; University of Fukui; Fukui Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantelis","family":"Sarafidis","sequence":"additional","affiliation":[{"name":"Department of Nephrology; Aristotle University, Hippokration Hospital; Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"},{"name":"Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J); University of Bari Aldo Moro; Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"supported by Cochrane Kidney and Transplant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"10.1002\/14651858.CD015907.pub2-BIB0001|cit1","unstructured":"World Health Organization Diabetes https:\/\/www.who.int\/health-topics\/diabetes"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"10085","key":"10.1002\/14651858.CD015907.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(17)30058-2","article-title":"Type 2 diabetes [Erratum in: Lancet. 2017 Jun 3;389(10085):2192]","volume":"389","author":"Chatterjee","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD015907.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"e011295","DOI":"10.1161\/JAHA.118.011295","article-title":"Diabetes mellitus-related all-cause and cardiovascular mortality in a national cohort of adults","volume":"19","author":"Raghavan","year":"2019","journal-title":"Journal of the American Heart Association"},{"issue":"1","key":"10.1002\/14651858.CD015907.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12955-020-01311-5","article-title":"Health-related quality of life and associated factors among patients with diabetes mellitus at the University of Gondar referral hospital","volume":"18","author":"Aschalew","year":"2020","journal-title":"Health & Quality Life Outcomes"},{"issue":"1","key":"10.1002\/14651858.CD015907.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"e001258","DOI":"10.1136\/bmjgh-2018-001258","article-title":"The costs of diabetes treatment in low- and middle-income countries: a systematic review","volume":"4","author":"Moucheraud","year":"2019","journal-title":"BMJ Global Health"},{"issue":"10159","key":"10.1002\/14651858.CD015907.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [Erratum in: Lancet. 2019 Jun 22;393(10190):e44]","volume":"392","author":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators","year":"2018","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0008|cit8","unstructured":"McDonald S Excell L Dent H ANZDATA 32nd Annual Report. 2009 Report: Data to 2008. Chapter 2: New patients commencing treatment in 2008 https:\/\/www.anzdata.org.au\/report\/anzdata-32nd-annual-report-2009\/"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s41100-018-0183-6","article-title":"Annual dialysis data report 2016, JSDT renal data registry","volume":"4","author":"Masakane","year":"2018","journal-title":"Renal Replacement Therapy"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0010|cit10","unstructured":"United States Renal Data System. 2018 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD https:\/\/www.niddk.nih.gov\/about-niddk\/strategic-plans-reports\/usrds\/prior-data-reports\/2018"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD015907.pub2-BIB0011|cit11","first-page":"S1","article-title":"Excerpts from the united states renal data system 2007 annual data report","volume":"51","author":"Collins","year":"2008","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD015907.pub2-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2337\/dc18-1485","article-title":"Cumulative risk of end-stage renal disease among patients with type 2 diabetes: a nationwide inception cohort study","volume":"42","author":"Finne","year":"2019","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD015907.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/ki.2014.296","article-title":"Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes","volume":"87","author":"Papademetriou","year":"2015","journal-title":"Kidney International"},{"issue":"8","key":"10.1002\/14651858.CD015907.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00204-016-1737-4","article-title":"The current role of thiazolidinediones in diabetes management","volume":"90","author":"Rizos","year":"2016","journal-title":"Archives of Toxicology"},{"issue":"1","key":"10.1002\/14651858.CD015907.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/s41598-017-01965-0","article-title":"Efficacy and safety of thiazolidinediones in diabetes patients with renal impairment: a systematic review and meta-analysis","volume":"7","author":"Wang","year":"2017","journal-title":"Scientific Reports"},{"issue":"6","key":"10.1002\/14651858.CD015907.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/pds.1722","article-title":"Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis","volume":"18","author":"Habib","year":"2009","journal-title":"Pharmacoepidemiology & Drug Safety"},{"issue":"1","key":"10.1002\/14651858.CD015907.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"e000481","DOI":"10.1136\/bmjdrc-2017-000481","article-title":"Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study","volume":"6","author":"Strongman","year":"2018","journal-title":"BMJ Open Diabetes Research & Care"},{"issue":"5","key":"10.1002\/14651858.CD015907.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5414\/CNP68287","article-title":"Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis","volume":"68","author":"Abe","year":"2007","journal-title":"Clinical Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD015907.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"e0129922","DOI":"10.1371\/journal.pone.0129922","article-title":"Thiazolidinediones and risk of long-term dialysis in diabetic patients with advanced chronic kidney disease: a nationwide cohort study","volume":"10","author":"Chen","year":"2015","journal-title":"PloS ONE [Electronic Resource]"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0020|cit20","doi-asserted-by":"crossref","unstructured":"KDIGO Working Group KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease https:\/\/kdigo.org\/wp-content\/uploads\/2022\/10\/KDIGO-2022-Clinical-Practice-Guideline-for-Diabetes-Management-in-CKD.pdf","DOI":"10.22141\/2307-1257.10.4.2021.247896"},{"issue":"9493","key":"10.1002\/14651858.CD015907.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD015907.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/dom.12487","article-title":"Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial","volume":"17","author":"Florez","year":"2015","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"9681","key":"10.1002\/14651858.CD015907.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD015907.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/medicina58101475","article-title":"An update on the current and emerging use of thiazolidinediones for type 2 diabetes","volume":"58","author":"Giglio","year":"2022","journal-title":"Medicina (Kaunas, Lithuania)"},{"issue":"2 Pt 2","key":"10.1002\/14651858.CD015907.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1161\/01.HYP.37.2.722","article-title":"Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells","volume":"37","author":"Nicholas","year":"2001","journal-title":"Hypertension"},{"issue":"7","key":"10.1002\/14651858.CD015907.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/sj.ki.5001620","article-title":"Protection of the kidney by thiazolidinediones: an assessment from bench to bedside","volume":"70","author":"Sarafidis","year":"2006","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD015907.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14740330802597821","article-title":"How safe is the use of thiazolidinediones in clinical practice?","volume":"8","author":"Rizos","year":"2009","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00424-007-0401-5","article-title":"Lack of the serum and glucocorticoid-inducible kinase SGK1 attenuates the volume retention after treatment with the PPAR gamma agonist pioglitazone","volume":"456","author":"Artunc","year":"2008","journal-title":"Pflugers Archiv: European Journal of Physiology"},{"issue":"3","key":"10.1002\/14651858.CD015907.pub2-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00232-010-9297-7","article-title":"Stimulation of ENaC activity by rosiglitazone is PPAR\u03b3-dependent and correlates with SGK1 expression increase","volume":"236","author":"Renauld","year":"2010","journal-title":"Journal of Membrane Biology"},{"issue":"2","key":"10.1002\/14651858.CD015907.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2215\/CJN.06330612","article-title":"Effect of spironolactone and amiloride on thiazolidinedione-induced fluid retention in South Indian patients with type 2 diabetes","volume":"8","author":"Viswanathan","year":"2013","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"5","key":"10.1002\/14651858.CD015907.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3390\/biomedicines12051098","article-title":"Diabetes and renal complications: an overview on pathophysiology, biomarkers and therapeutic interventions","volume":"12","author":"Jha","year":"2024","journal-title":"Biomedicines"},{"issue":"1","key":"10.1002\/14651858.CD015907.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ecl.2017.10.006","article-title":"Managing diabetes and cardiovascular risk in chronic kidney disease patients","volume":"47","author":"Lovre","year":"2018","journal-title":"Endocrinology & Metabolism Clinics of North America"},{"issue":"9","key":"10.1002\/14651858.CD015907.pub2-BIB0033|cit33","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011798.pub2","article-title":"Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease","author":"Lo","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD015907.pub2-BIB0034|cit34","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015906","article-title":"Dipeptidyl peptidase 4 (DPP-4) inhibitors for people with chronic kidney disease and diabetes","author":"Natale","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD015907.pub2-BIB0035|cit35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015849.pub2","article-title":"Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes","author":"Natale","year":"2025","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD015907.pub2-BIB0036|cit36","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015588.pub2","article-title":"Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes","author":"Natale","year":"2024","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD015907.pub2-BIB0037|cit37","first-page":"1","article-title":"Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Levin","year":"2012","journal-title":"Kidney International Supplements"},{"issue":"1","key":"10.1002\/14651858.CD015907.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.dsx.2018.04.013","article-title":"Effect of pioglitazone on decreasing of proteinuria in type 2 diabetic patients with nephropathy","volume":"13","author":"Pourshabanan","year":"2019","journal-title":"Diabetes & Metabolic Syndrome"},{"issue":"10","key":"10.1002\/14651858.CD015907.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"e0206722","DOI":"10.1371\/journal.pone.0206722","article-title":"Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: a randomized controlled trial","volume":"13","author":"Satirapoj","year":"2018","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD015907.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"S484","DOI":"10.1007\/s00125-016-4046-9","article-title":"Effects of pioglitazone add-on treatment on blood glucose levels and insulin resistance in patients with type 2 diabetic nephropathy receiving sitagliptin [abstract no: 1009]","volume":"1","author":"Yasuda","year":"2016","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0041|cit41","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological expectations of Cochrane intervention reviews. Cochrane: London, Version August 2023 Available from https:\/\/community.cochrane.org\/mecir-manual"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0043|cit43","unstructured":"The SONG Handbook Version 1.0 https:\/\/www.songinitiative.org\/reports-and-publications\/ 2017"},{"issue":"1","key":"10.1002\/14651858.CD015907.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"e000700","DOI":"10.1136\/bmjdrc-2019-000700","article-title":"Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes (SCORE-IT): a patient and healthcare professional consensus on a core outcome set for type 2 diabetes","volume":"7","author":"Harman","year":"2019","journal-title":"BMJ Open Diabetes Research & Care"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0045|cit45","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 (archived) Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0046|cit46","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0047|cit47","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial (chapter last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from www.training.cochrane.org\/handbook"},{"issue":"7414","key":"10.1002\/14651858.CD015907.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0050|cit50","unstructured":"Eldridge S Campbell M Campbell M Dahota A Giraudeau B Higgins J Revised Cochrane risk of biastool for randomized trials (RoB 2.0). Additional considerations for cluster-randomized trials https:\/\/www.riskofbias.info\/welcome\/rob-2-0-tool\/archive-rob-2-0-cluster-randomized-trials-2016 (accessed 09 October 2025)"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0051|cit51","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials (chapter last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0052|cit52","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing evidence in a meta-analysis (chapter last updated August 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0053|cit53","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence (chapter last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.training.cochrane.org\/handbook"},{"issue":"7650","key":"10.1002\/14651858.CD015907.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD015907.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0056|cit56","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0057|cit57","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions (last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.training.cochrane.org\/handbook"},{"issue":"3","key":"10.1002\/14651858.CD015907.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"220","DOI":"10.5414\/CNP70220","article-title":"Clinical investigation of the effects of pioglitazone on the improvement of insulin resistance and blood pressure in type 2-diabetic patients undergoing hemodialysis","volume":"70","author":"Abe","year":"2008","journal-title":"Clinical Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD015907.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.2215\/CJN.09291010","article-title":"Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy","volume":"6","author":"Lachin","year":"2011","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"8","key":"10.1002\/14651858.CD015907.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.2337\/db06-0116","article-title":"Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes","volume":"55","author":"Kahn","year":"2006","journal-title":"Diabetes"},{"issue":"12","key":"10.1002\/14651858.CD015907.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.2337\/diabetes.53.12.3193","article-title":"Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe","volume":"53","author":"Zinman","year":"2004","journal-title":"Diabetes"},{"issue":"23","key":"10.1002\/14651858.CD015907.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy [Erratum appears in N Engl J Med. 2007 Mar 29;356(13):1387-8]","volume":"355","author":"Kahn","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD015907.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.amjmed.2003.07.023","article-title":"Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial","volume":"116","author":"Aljabri","year":"2004","journal-title":"American Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD015907.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1093\/ndt\/gfr049","article-title":"Rosiglitazone does not improve vascular function in subjects with chronic kidney disease","volume":"26","author":"Chan","year":"2011","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD015907.pub2-BIB0065|cit65","first-page":"A132","article-title":"Rosiglitazone lowers insulin resistance, inflammation and von Willebrand factor in patients with stage 1-4 chronic kidney disease [abstract no: 126]","volume":"13","author":"Chan","year":"2008","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0066|cit66","first-page":"397A","article-title":"Effect of rosiglitazone on insulin sensitivity, adiponectin and markers of bone turnover in chronic kidney disease [abstract no: F-PO1243]","volume":"20","author":"Chan","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD015907.pub2-BIB0067|cit67","first-page":"A133","article-title":"Effect of rosiglitazone on arterial function and stiffness in patients with stage 3 to 4 chronic kidney disease [abstract no: 127]","volume":"13","author":"Chan","year":"2008","journal-title":"Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD015907.pub2-BIB0068|cit68","first-page":"A132","article-title":"Safety and tolerability of rosiglitazone in stage 3-4 chronic kidney disease [abstract no: 125]","volume":"13","author":"Chan","year":"2008","journal-title":"Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD015907.pub2-BIB0069|cit69","first-page":"42","article-title":"Impact of rosiglitazone on markers of bone metabolism in chronic kidney disease [abstract no: 060]","volume":"15","author":"Chan","year":"2010","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0070|cit70","unstructured":"Chan D Watts G Irish A Dogra G Rosiglitazone improves inflammation and in vivo marker of endothelial function but not arterial function and stiffness in patients with stage 3 - 4 chronic kidney disease [abstract no: SA181] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"issue":"3","key":"10.1002\/14651858.CD015907.pub2-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/dom.15388","article-title":"Evaluation of the efficacy of a combination of dapagliflozin and lobeglitazone on glucose concentrations and body fat in patients with type 2 diabetes: location-F study","volume":"26","author":"Choe","year":"2024","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"9","key":"10.1002\/14651858.CD015907.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/j.clinthera.2007.09.011","article-title":"A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy","volume":"29","author":"Davidson","year":"2007","journal-title":"Clinical Therapeutics"},{"issue":"11","key":"10.1002\/14651858.CD015907.pub2-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"2351\u201366","DOI":"10.1007\/s13300-024-01638-y","article-title":"Efficacy and safety of pioglitazone\/metformin fixed-dose combination versus uptitrated metformin in patients with type 2 diabetes without adequate glycemic control: a randomized clinical trial","volume":"15","author":"Guo","year":"2024","journal-title":"Diabetes Therapy"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"S134","DOI":"10.1007\/s00125-023-05969-6","article-title":"Efficacy and safety of pioglitazone\/metformin fixed-dose formulation vs uptitrated metformin in type 2 diabetes with inadequate glycaemic control: a randomised trial [abstract]","volume":"66","author":"Guo","year":"2023","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"110872","DOI":"10.1016\/j.diabres.2023.110872","article-title":"Comparison of therapeutic efficacy and safety of sitagliptin, dapagliflozin, or lobeglitazone adjunct therapy in patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea and metformin: third agent study","volume":"203","author":"Hong","year":"2023","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"20","key":"10.1002\/14651858.CD015907.pub2-BIB0076|cit76","first-page":"27","article-title":"Effect of rosiglitazone on serum CRP and plasma PAI-1 in patients with early type 2 diabetic nephropathy","volume":"34","author":"Hu","year":"2007","journal-title":"Central Plains Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD015907.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1210\/jcem.86.1.7157","article-title":"Rosiglitazone monotherapy is effective in patients with type 2 diabetes.[Erratum appears in J Clin Endocrinol Metab. 2002 Feb;2(1):iv; Erratum appears in J Clin Endocrinol Metab 2001 Apr;86(4):1659]","volume":"86","author":"Lebovitz","year":"2001","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"6","key":"10.1002\/14651858.CD015907.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"2188-98","DOI":"10.1111\/dom.15526","article-title":"A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin","volume":"26","author":"Lim","year":"2024","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"11","key":"10.1002\/14651858.CD015907.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/sj.ki.5002516","article-title":"Rosiglitazone decreases albuminuria in type 2 diabetic patients","volume":"72","author":"Miyazaki","year":"2007","journal-title":"Kidney International"},{"issue":"10","key":"10.1002\/14651858.CD015907.pub2-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1053\/meta.2001.26703","article-title":"Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria","volume":"50","author":"Nakamura","year":"2001","journal-title":"Metabolism: Clinical & Experimental"},{"issue":"6","key":"10.1002\/14651858.CD015907.pub2-BIB0081|cit81","first-page":"863","article-title":"Effect of pioglitazone on dyslipidemia in hemodialysis patients with type 2 diabetes","volume":"23","author":"Nakamura","year":"2001","journal-title":"Renal Failure"},{"issue":"5","key":"10.1002\/14651858.CD015907.pub2-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"915-28","DOI":"10.4093\/dmj.2023.0259","article-title":"Efficacy and safety of alogliptin-pioglitazone combination for type 2 diabetes mellitus poorly controlled with metformin: a multicenter, double-blind randomized trial","volume":"48","author":"Park","year":"2024","journal-title":"Diabetes & Metabolism Journal"},{"issue":"23-24","key":"10.1002\/14651858.CD015907.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00508-009-1279-3","article-title":"Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial","volume":"121","author":"Petrica","year":"2009","journal-title":"Wiener Klinische Wochenschrift"},{"issue":"9493","key":"10.1002\/14651858.CD015907.pub2-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD015907.pub2-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1681\/ASN.2007060678","article-title":"Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease [Erratum in: J Am Soc Nephrol. 2016 Sep;27(9):2918. doi: 10.1681\/ASN.2016060616]","volume":"19","author":"Schneider","year":"2008","journal-title":"Journal American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD015907.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2337\/diacare.27.1.141","article-title":"One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes","volume":"27","author":"Hanefeld","year":"2004","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1002\/14651858.CD015907.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00125-005-1751-1","article-title":"Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes","volume":"48","author":"Charbonnel","year":"2005","journal-title":"Diabetologia"},{"issue":"4","key":"10.1002\/14651858.CD015907.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1464-5491.2004.01426.x","article-title":"A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial","volume":"22","author":"Charbonnel","year":"2005","journal-title":"Diabetic Medicine"},{"issue":"12","key":"10.1002\/14651858.CD015907.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"6068","DOI":"10.1210\/jc.2003-030861","article-title":"Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial [Erratum appears in J Clin Endocrinol Metab. 2005 Feb;90(2):746]","volume":"89","author":"Schernthaner","year":"2004","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD015907.pub2-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"136-41","DOI":"10.47583\/ijpsrr.2023.v81i02.023","article-title":"Comparative study of efficacy and safety of lobeglitazone versus pioglitazone as add on therapy to metformin and vildagliptin in patients of type 2 diabetes mellitus","volume":"81","author":"Raman","year":"2023","journal-title":"International Journal of Pharmaceutical Sciences Review & Research"},{"issue":"7","key":"10.1002\/14651858.CD015907.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/dc11-1693","article-title":"Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015907.pub2-BIB0092|cit92","first-page":"A270","article-title":"Dapagliflozin added-on to pioglitazone reduces HbA1c and mitigates weight gain with low incidence of hypoglycemia in type 2 diabetes [abstract no: 986-P]","volume":"60","author":"Rosenstock","year":"2011","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015907.pub2-BIB0093|cit93","first-page":"S347","article-title":"Dapagliflozin added-on to pioglitazone is effective in improving glycaemic control and attenuates weight gain without increasing hypoglycaemia in patients with type 2 diabetes [abstract no: 851]","volume":"54","author":"Vico","year":"2011","journal-title":"Diabetologia"},{"issue":"2","key":"10.1002\/14651858.CD015907.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijcard.2010.08.037","article-title":"Effects of high dose aleglitazar on renal function in patients with type 2 diabetes","volume":"151","author":"Herz","year":"2011","journal-title":"International Journal of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD015907.pub2-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"923-31","DOI":"10.1111\/pedi.13062","article-title":"Circulating adhesion molecules and associations with HbA1c, hypertension, nephropathy, and retinopathy in the Treatment Options for type 2 Diabetes in Adolescent and Youth study","volume":"21","author":"Tryggestad","year":"2020","journal-title":"Pediatric Diabetes"},{"issue":"9","key":"10.1002\/14651858.CD015907.pub2-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"1597-607","DOI":"10.2337\/dc23-2441","article-title":"Circulating metabolite biomarkers of glycemic control in youth-onset type 2 diabetes","volume":"47","author":"Chen","year":"2024","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD015907.pub2-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"E240447","DOI":"10.1001\/jamanetworkopen.2024.0447","article-title":"Growth hormone mediators and glycemic control in youths with type 2 diabetes a secondary analysis of a randomized clinical trial","volume":"7","author":"Lu","year":"2024","journal-title":"JAMA Network Open"},{"issue":"8","key":"10.1002\/14651858.CD015907.pub2-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"3137-46","DOI":"10.1111\/dom.15641","article-title":"Pioglitazone reduces serum ketone bodies in sodium-glucose cotransporter-2 inhibitor-treated non-obese type 2 diabetes: a single-centre, randomized, crossover trial","volume":"26","author":"Yang","year":"2024","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD015907.pub2-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"385-91","DOI":"10.1515\/hmbci-2022-0070","article-title":"Effects of pioglitazone and linagliptin on glycemic control, lipid profile and hs-CRP in metformin-treated patients with type 2 diabetes: a comparative study","volume":"44","author":"Zamani","year":"2023","journal-title":"Hormone Molecular Biology & Clinical Investigation"},{"issue":"5","key":"10.1002\/14651858.CD015907.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3747\/pdi.2011.00116","article-title":"Twelve weeks of pioglitazone therapy significantly attenuates dysmetabolism and reduces inflammation in continuous ambulatory peritoneal dialysis patients--a randomized crossover trial","volume":"32","author":"Li","year":"2012","journal-title":"Peritoneal Dialysis International"},{"issue":"7","key":"10.1002\/14651858.CD015907.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.2337\/diabetes.54.7.2206","article-title":"Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients","volume":"54","author":"Pistrosch","year":"2005","journal-title":"Diabetes"},{"issue":"18","key":"10.1002\/14651858.CD015907.pub2-BIB0102|cit102","first-page":"1484","article-title":"The effects of pioglitazone on urinary albumin in excretion rate of early diabetic nephropathy","volume":"8","author":"Cao","year":"2005","journal-title":"Chinese General Practice"},{"issue":"1","key":"10.1002\/14651858.CD015907.pub2-BIB0103|cit103","first-page":"50","article-title":"Clinical observation of pioglitazone in diabetic nephropathy","volume":"10","author":"Chen","year":"2004","journal-title":"International Medical Healthcare Guiding Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015907.pub2-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2337\/db23-165-LB","article-title":"Circulating metabolomic biomarkers of glycemic control in youth with type 2 diabetes (T2D)","volume":"72","author":"Chen","year":"2023","journal-title":"Diabetes"},{"issue":"7","key":"10.1002\/14651858.CD015907.pub2-BIB0105|cit105","first-page":"1194","article-title":"Observation on the therapeutic effect of rosiglitazone combined with metformin on diabetic nephropathy","volume":"6","author":"Chen","year":"2006","journal-title":"China Tropical Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015907.pub2-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3969\/j.issn.1672-7347.2012.01.013","article-title":"Puerarin combined with avandia for diabetic nephropathy","volume":"37","author":"Hou","year":"2012","journal-title":"Zhong Nan da Xue Xue Bao. Yi Xue Ban [Journal of Central South University. Medical Sciences]"},{"issue":"6","key":"10.1002\/14651858.CD015907.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2265.2010.03878.x","article-title":"Hydrochloride pioglitazone decreases urinary cytokines excretion in type 2 diabetes","volume":"73","author":"Hu","year":"2010","journal-title":"Clinical Endocrinology"},{"issue":"7","key":"10.1002\/14651858.CD015907.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1365-2362.2010.02302.x","article-title":"Hydrochloride pioglitazone decreases urinary TGF-beta1 excretion in type 2 diabetics","volume":"40","author":"Hu","year":"2010","journal-title":"European Journal of Clinical Investigation"},{"issue":"15","key":"10.1002\/14651858.CD015907.pub2-BIB0109|cit109","first-page":"2162","article-title":"Rosiglitazone in urinary protein of diabetic nephropathy","volume":"13","author":"Shata'er","year":"2007","journal-title":"Chinese Medicine Clinical Research - Chinese Magazine of Clinical Medicinal Professional Research"},{"issue":"2","key":"10.1002\/14651858.CD015907.pub2-BIB0110|cit110","first-page":"101","article-title":"Effect of pioglitazone on serum advanced glycosylation end product peptide and monocyte chemoattractant protein-1 in type 2 diabetic patients","volume":"32","author":"Sun","year":"2006","journal-title":"Jiangsu Medical Journal"},{"issue":"2","key":"10.1002\/14651858.CD015907.pub2-BIB0111|cit111","first-page":"176","article-title":"Observation of therapeutic effect of rosiglitazone in type 2 diabetes with nephropathy","volume":"12","author":"Tan","year":"2006","journal-title":"Journal of Modern Clinical Medical Bioengineering"},{"issue":"7","key":"10.1002\/14651858.CD015907.pub2-BIB0112|cit112","first-page":"47","article-title":"Treatment effect of rosiglitazone in type 2 diabetic nephropathy","volume":"27","author":"Tang","year":"2007","journal-title":"Clinical Medicine"},{"issue":"6","key":"10.1002\/14651858.CD015907.pub2-BIB0113|cit113","first-page":"13","article-title":"Renal protecting effects of pioglitazone in diabetic nephropathy","volume":"24","author":"Wang","year":"2004","journal-title":"Clinical Medicine"},{"issue":"11A","key":"10.1002\/14651858.CD015907.pub2-BIB0114|cit114","first-page":"36","article-title":"Rosiglitazone affects albuminuria in type 2 diabetes","volume":"28","author":"Wang","year":"2005","journal-title":"Journal of Postgraduates of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD015907.pub2-BIB0115|cit115","first-page":"692","article-title":"Rosiglitazone affects urinary protein excretory rate and C-reactive protein in diabetic nephropathy","volume":"5","author":"Wang","year":"2005","journal-title":"Zhong Guo Wu Zhen Xue za Zhi [Chinese Journal of Misdiagnostics]"},{"issue":"8","key":"10.1002\/14651858.CD015907.pub2-BIB0116|cit116","first-page":"711","article-title":"Effects of rosiglitazone in type 2 diabetic nephropathy","volume":"21","author":"Wang","year":"2005","journal-title":"Clinical Medicine of China"},{"issue":"4","key":"10.1002\/14651858.CD015907.pub2-BIB0117|cit117","first-page":"808","article-title":"Twenty-two cases diagnosed with diabetic nephropathy treated with pioglitazone combined prostaglandin","volume":"41","author":"Wang","year":"2006","journal-title":"Zheng Zhou da Xue Xue Bao (Yi Xue Ban) [Journal of Zhengzhou University (Medical Science)]"},{"issue":"2","key":"10.1002\/14651858.CD015907.pub2-BIB0118|cit118","first-page":"95","article-title":"Effect of rosiglitazone in early stage of diabetic nephropathy","volume":"7","author":"Wang","year":"2008","journal-title":"Journal of Clinical and Experimental Medicine"},{"issue":"11A","key":"10.1002\/14651858.CD015907.pub2-BIB0119|cit119","first-page":"55","article-title":"Rosiglitazone's effect to trace urinary protein and C-reactive protein in patients with diabetic nephropathy","volume":"29","author":"Xie","year":"2006","journal-title":"Chinese Journal of Postgraduate Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015907.pub2-BIB0120|cit120","first-page":"56","article-title":"Observation of trace urinary protein and C-reactive protein level of pioglitazone treating early diabetic nephropathy","volume":"34","author":"Xu","year":"2005","journal-title":"Chongqin Medicine Journal"},{"issue":"10","key":"10.1002\/14651858.CD015907.pub2-BIB0121|cit121","first-page":"1432","article-title":"Clinical observation of treatment effect of enalapril combined rosiglitazone in early stage diabetic nephropathy","volume":"27","author":"Zhang","year":"2007","journal-title":"Zhong Guo Yi Yuan Yao Xue za Zhi [Chinese Journal of Hospital Pharmacy]"},{"issue":"14","key":"10.1002\/14651858.CD015907.pub2-BIB0122|cit122","first-page":"1037","article-title":"Effect of rosiglitazone in microalbuminuria in type 2 diabetic nephropathy","volume":"22","author":"Zhao","year":"2007","journal-title":"Clinical Focus"},{"issue":"6","key":"10.1002\/14651858.CD015907.pub2-BIB0123|cit123","first-page":"36","article-title":"The clinical observation of benazepril combined with rosiglitazone in patients with diabetic nephropathy","volume":"34","author":"Zheng","year":"2006","journal-title":"Academic Journal of GuangZhou Medical College"},{"issue":"2","key":"10.1002\/14651858.CD015907.pub2-BIB0124|cit124","first-page":"72","article-title":"Renal protection effects of rosiglitazone in diabetic nephropathy","volume":"6","author":"Zhou","year":"2003","journal-title":"Liaoning Pharmacy & Clinical Remedies"},{"issue":"12","key":"10.1002\/14651858.CD015907.pub2-BIB0125|cit125","first-page":"931","article-title":"Observation of curative effect of rosiglitazone on delaying progression of type 2 diabetic nephropathy","volume":"16","author":"Zou","year":"2005","journal-title":"China Pharmacy"},{"issue":"1","key":"10.1002\/14651858.CD015907.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000337334","article-title":"Comparison of the effects of pioglitazone versus placebo when given in addition to standard insulin treatment in patients with type 2 diabetes mellitus requiring hemodialysis: results from the pioren study","volume":"2","author":"Galle","year":"2012","journal-title":"Nephron Extra"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015907.pub2-BIB0127|cit127","first-page":"A315","article-title":"Use of pioglitazone vs. placebo in addition to standard insulin treatment in patients with type 2 diabetes mellitus requiring hemodialysis treatment [abstract no: 1148-P]","volume":"60","author":"Pfutzner","year":"2011","journal-title":"Diabetes"},{"issue":"12","key":"10.1002\/14651858.CD015907.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1055\/s-0032-1314836","article-title":"Effect of thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy","volume":"44","author":"Pistrosch","year":"2012","journal-title":"Hormone & Metabolic Research"},{"issue":"4","key":"10.1002\/14651858.CD015907.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/j.ajkd.2005.06.020","article-title":"Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis","volume":"46","author":"Wong","year":"2005","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD015907.pub2-BIB0130|cit130","doi-asserted-by":"publisher","first-page":"32-42","DOI":"10.59556\/japi.71.0445","article-title":"Randomized, double-blind, phase III trial of lobeglitazone add-on to metformin in type 2 diabetes (SENSITIZE INDIA)","volume":"72","author":"Joshi","year":"2024","journal-title":"Journal of the Association of Physicians of India"},{"issue":"3","key":"10.1002\/14651858.CD015907.pub2-BIB0131|cit131","doi-asserted-by":"publisher","first-page":"154-9","DOI":"10.47583\/ijpsrr.2024.v84i03.022","article-title":"Efficacy and safety of lobeglitazone versus pioglitazone as add on therapy to metformin and vildagliptin in patients of type 2 diabetes mellitus: a randomised controlled trial","volume":"84","author":"Kumar","year":"2024","journal-title":"International Journal of Pharmaceutical Sciences Review & Research"},{"issue":"5","key":"10.1002\/14651858.CD015907.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5414\/CNP68287","article-title":"Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis","volume":"68","author":"Abe","year":"2007","journal-title":"Clinical Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD015907.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1517\/14656566.2010.495119","article-title":"Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis","volume":"11","author":"Abe","year":"2010","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"6","key":"10.1002\/14651858.CD015907.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s10157-011-0512-3","article-title":"Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study","volume":"15","author":"Morikawa","year":"2011","journal-title":"Clinical & Experimental Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD015907.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.2337\/diacare.21.12.2135","article-title":"Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy","volume":"21","author":"Imano","year":"1998","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1002\/14651858.CD015907.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1056-8727(00)00124-0","article-title":"Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients","volume":"14","author":"Nakamura","year":"2000","journal-title":"Journal of Diabetes & its Complications"},{"issue":"4","key":"10.1002\/14651858.CD015907.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1046\/j.1464-5491.2001.00463.x","article-title":"Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in type 2 diabetic patients with microalbuminuria or macroalbuminuria","volume":"18","author":"Nakamura","year":"2001","journal-title":"Diabetic Medicine"},{"issue":"10","key":"10.1002\/14651858.CD015907.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.metabol.2004.05.013","article-title":"Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients","volume":"53","author":"Nakamura","year":"2004","journal-title":"Metabolism: Clinical & Experimental"},{"issue":"5","key":"10.1002\/14651858.CD015907.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/dmrr.633","article-title":"Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria","volume":"22","author":"Nakamura","year":"2006","journal-title":"Diabetes\/Metabolism Research Reviews"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0140|cit140","unstructured":"Shiga progression of diabetes, nephropathy and retinopathy (SHIP-DINER) https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00846716"},{"issue":"3","key":"10.1002\/14651858.CD015907.pub2-BIB0141|cit141","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.metabol.2003.10.025","article-title":"Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes","volume":"53","author":"Yanagawa","year":"2023","journal-title":"Metabolism: Clinical & Experimental"},{"issue":"9","key":"10.1002\/14651858.CD015907.pub2-BIB0142|cit142","doi-asserted-by":"publisher","first-page":"662-9","DOI":"10.1016\/j.clinthera.2024.06.023","article-title":"Efficacy and safety of pioglitazone add-on in patients with type 2 diabetes mellitus inadequately controlled with metformin and dapagliflozin: a multicenter, randomized, double-blind, and placebo-controlled study","volume":"46","author":"Cho","year":"2024","journal-title":"Clinical Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD015907.pub2-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"937-48","DOI":"10.4093\/dmj.2023.0314","article-title":"Pioglitazone as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled with dapagliflozin and metformin: double-blind, randomized, placebo-controlled trial","volume":"48","author":"Heo","year":"2024","journal-title":"Diabetes & Metabolism Journal"},{"issue":"2","key":"10.1002\/14651858.CD015907.pub2-BIB0144|cit144","first-page":"170","article-title":"Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy","volume":"89","author":"Katavetin","year":"2006","journal-title":"Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]"},{"issue":"5","key":"10.1002\/14651858.CD015907.pub2-BIB0145|cit145","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s11255-022-03420-0","article-title":"Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial","volume":"55","author":"Triwatana","year":"2023","journal-title":"International Urology & Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015907.pub2-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/nep.13944","article-title":"Effect of pioglitazone on serum FGF-23 levels in patients with diabetic kidney disease: a randomized controlled trial [abstract no: P021]","volume":"26","author":"Triwatana","year":"2021","journal-title":"Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD015907.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1523-1755.2005.00416.x","article-title":"A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy","volume":"68","author":"Agarwal","year":"2005","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD015907.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"F600","DOI":"10.1152\/ajprenal.00289.2005","article-title":"Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy","volume":"290","author":"Agarwal","year":"2006","journal-title":"American Journal of Physiology - Renal Physiology"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0149|cit149","first-page":"232A","article-title":"Pioglitazone plasma hsCRP and HMW adiponectin in hemodialysis patients [abstract no: TH-PO586]","volume":"23","author":"Beddhu","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD015907.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1385\/ENDO:28:2:181","article-title":"The metabolic effects of troglitazone in patients with diabetes and end-stage renal disease","volume":"28","author":"Mohideen","year":"2005","journal-title":"Endocrine"},{"issue":"7","key":"10.1002\/14651858.CD015907.pub2-BIB0151|cit151","first-page":"555","article-title":"Observation of treatment effect of pioglitazone in diabetic kidney disease","volume":"19","author":"Fang","year":"2007","journal-title":"Modern Practical Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015907.pub2-BIB0152|cit152","first-page":"45","article-title":"Observation of therapeutic effects of rosiglitazone in type2 diabetic nephropathy","volume":"24","author":"Gan","year":"2007","journal-title":"Chinese Medical Journal of Metallurgical Industry"},{"issue":"20","key":"10.1002\/14651858.CD015907.pub2-BIB0153|cit153","first-page":"1497","article-title":"Short-term improvement effects of pioglitazone combined prostaglandin E1 in diabetic nephropathy","volume":"21","author":"Gao","year":"2006","journal-title":"Clinical Focus"},{"issue":"2","key":"10.1002\/14651858.CD015907.pub2-BIB0154|cit154","first-page":"126","article-title":"Effects of rosiglitazone on urinary albumin excretion in patients with early diabetic nephropathy","volume":"15","author":"Gao","year":"2007","journal-title":"Zhong Guo Man Xing Bing Yu Fang Yu Kong Zhi [Chinese Journal of Prevention and Control of Chronic Non-Communicable Diseases]"},{"issue":"3","key":"10.1002\/14651858.CD015907.pub2-BIB0155|cit155","first-page":"176","article-title":"Pioglitazone combined fosinopril in treating 52 patients with type 2 diabetes and microalbuminuria","volume":"17","author":"Gao","year":"2007","journal-title":"Journal of New Medicine"},{"issue":"6","key":"10.1002\/14651858.CD015907.pub2-BIB0156|cit156","first-page":"704","article-title":"Observation of therapeutic effects of pioglitazone in early diabetic nephropathy","volume":"20","author":"He","year":"2004","journal-title":"Journal of Practical Medicine"},{"issue":"3","key":"10.1002\/14651858.CD015907.pub2-BIB0157|cit157","first-page":"324","article-title":"Observation of therapeutic effects of rosiglitazone in diabetic nephropathy","volume":"17","author":"Huang","year":"2004","journal-title":"Acta Medicinae Sinica"},{"issue":"4","key":"10.1002\/14651858.CD015907.pub2-BIB0158|cit158","first-page":"211","article-title":"Effect of rosiglitazone on urinary monocyte chemoattractant protein-1 in patients with diabetic nephropathy","volume":"25","author":"Huang","year":"2006","journal-title":"Journal of Yunyang Medical College"},{"issue":"7","key":"10.1002\/14651858.CD015907.pub2-BIB0159|cit159","first-page":"51","article-title":"Effects of pioglitazone on changes of haemorrheology and insulin resistance in patients with early diabetic nephropathy","volume":"13","author":"Huang","year":"2007","journal-title":"IMHGN - International Medicine & Health Guidance News"},{"issue":"9","key":"10.1002\/14651858.CD015907.pub2-BIB0160|cit160","first-page":"1432","article-title":"Observation of effect of rosiglitazone in type 2 diabetes with trace urinary protein","volume":"4","author":"Li","year":"2004","journal-title":"Zhong Guo Wu Zhen Xue za Zhi [Chinese Journal of Misdiagnostics]"},{"issue":"9","key":"10.1002\/14651858.CD015907.pub2-BIB0161|cit161","first-page":"31","article-title":"Effects of pioglitazone on microalbuminuria of early diabetic nephropathy","volume":"27","author":"Li","year":"2006","journal-title":"Journal of Medical Forum"},{"issue":"1","key":"10.1002\/14651858.CD015907.pub2-BIB0162|cit162","first-page":"58","article-title":"Rosiglitazone affect type 2 diabetic nephropathy","volume":"21","author":"Li","year":"2008","journal-title":"Zhong Guo Chang Kuang Yi Xue [Chinese Medicine of Factory and Mine]"},{"issue":"6","key":"10.1002\/14651858.CD015907.pub2-BIB0163|cit163","first-page":"593","article-title":"Pioglitazone affects the urinary protein extracting rate in early diabetic nephropathy","volume":"34","author":"Su","year":"2006","journal-title":"Youjiang Medical Journal"},{"issue":"10","key":"10.1002\/14651858.CD015907.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1097\/01.hjh.0000244955.39491.88","article-title":"Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria","volume":"24","author":"Bakris","year":"2006","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0165|cit165","unstructured":"Effectiveness and safety of a new diabetes medication with conventional treatment in patients with type 2 diabetes https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2024\/02\/062299"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0166|cit166","unstructured":"A clinical trial to study the effect of antidiabetic drug Pioglitazone in patients with Type 2 Diabetes Mellitus when given as low dose or twice weekly dose https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2024\/02\/062959"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0167|cit167","unstructured":"A clinical trial to study the effect and safety of lobeglitazone Vs. pioglitazone in diabetic patients https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2024\/03\/063774"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0168|cit168","unstructured":"A Phase 3 study will assess the efficacy, safety, and tolerability of a fixed-dose combination (FDC) of dapagliflozin 10mg and pioglitazone 15mg tablets versus separate doses of Forxiga 10mg and Pioglit\u00ae 15mg in Type 2 diabetes patients inadequately controlled on metformin monotherapy https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2024\/09\/073221"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0169|cit169","unstructured":"Evaluation of islet function and safety of Henagliflozin combined with metformin after short-term intensive insulin therapy in newly diagnosed type 2 diabetes https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2300078750 2023"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0170|cit170","unstructured":"Enavogliflozin vs. pioglitazone on glucose and atherosclerosis https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT06399835"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0171|cit171","unstructured":"The determination of the comparative effect of ertugliflozin, pioglitazone, and metformin in patients of nonalcoholic fatty liver diseases in type 2 diabetes mellitus https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2300079249"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0172|cit172","unstructured":"A clinical trial to study the effect of two drugs, dapagliflozin 10mg and pioglitazone 15mg tablet in a healthy subject under fasting conditions to treat type-2 diabetes mellitus https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2023\/11\/059381"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0173|cit173","unstructured":"Efficacy and safety of pioglitazone combination therapy in type 2 diabetes patients on a background of empagliflozin with metformin https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT06571591"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0174|cit174","unstructured":"Clinical study to evaluate the efficacy and safety of Pioglitazone co-administration in patients with type II diabetes with insufficient glycemic control with Metformin and Empagliflozin combination therapy https:\/\/www.trialsearch.who.int\/Trial2.aspx?TrialID=CTIS2023-508924-36-00 ."},{"key":"10.1002\/14651858.CD015907.pub2-BIB0175|cit175","unstructured":"Comparative effectiveness of two initial combination therapies in patients with recent onset diabetes https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT06246799"},{"key":"10.1002\/14651858.CD015907.pub2-BIB0176|cit176","doi-asserted-by":"publisher","first-page":"7260","DOI":"10.3390\/jcm12237260","article-title":"Effect of antidiabetic drugs on bone health in patients with normal renal function and in chronic kidney disease (CKD): insight into clinical challenges in the treatment of type 2 diabetes","volume":"12","author":"Cipriani","journal-title":"Journal of Clinical Medicine"},{"issue":"5","key":"10.1002\/14651858.CD015907.pub2-BIB0177|cit177","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1210\/clinem\/dgz252","article-title":"Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis","volume":"105","author":"Zhou","year":"2020","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD015907.pub2-BIB0178|cit178","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.numecd.2011.11.005","article-title":"Glitazones in chronic kidney disease: potential and concerns [Erratum in: Nutr Metab Cardiovasc Dis. 2013 Jan;23(1):75]","volume":"22","author":"Bolignano","year":"2012","journal-title":"Nutrition, Metabolism, and Cardiovascular Diseases: NMCD"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:04:06Z","timestamp":1790143446000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015907.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":178,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015907.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]}}}